Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601128 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
A Phase 3 study, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT05601128: Completed Phase 3 study, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
NCT05601128 is a Phase 3 study that has completed, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 12 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05601128, a Phase 3 study, has completed, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment. This study is considered research and is voluntary.
Primary Outcome
Since this is primarily a pharmacokinetics study, this descriptive outcome will demonstrate plasma concentration measures (Ctrough) versus time profiles for CAB LA.
Interventions
- DRUG CAB + RPV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 3 |
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)34 total trials
What the finished NCT05601128 record still lists
NCT05601128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which CAB + RPV is the first listed.
NCT05601128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05601128 about?
NCT05601128 is a clinical study titled "A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA". The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment. This study is considered research and is voluntary.
What is the current status of trial NCT05601128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2023-01-01. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT05601128?
The interventions under investigation include: CAB + RPV (DRUG).
Who is sponsoring clinical trial NCT05601128?
This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05601128's enrollment target sits among peer trials
12 1984th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI